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S)-(2,3-bis(palmitoyloxy)-(2RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser(S)-Lys

Introduction
Persistent inflammation has been implicated in the pathogenesis of diverse chronic diseases such as rheumatoid arthritis, atherosclerosis, chronic hepatitis and diabetes. The Toll-like receptor (TLR) family members are key contributors to these pro-inflammatory conditions. These pattern recognition receptors respond to molecular patterns in components of bacteria and viruses. In addition to their role in detecting microbial associated molecular patterns, the TLRs can also sense endogenous ligands and have been implicated in perpetuating inflammatory cascades in the absence of invading microbes or other pathogens. Identifying agents capable of safely modulating individual TLR activity is an area of intense investigation.
Among TLRs, TLR4 was discovered as a sensing receptor for bacterial lipopolysaccharide (LPS) (Beutler, 2000) . Membrane-bound TLR4 recognizes LPS and signals with enhanced efficiency after forming a receptor complex with accessory proteins including myeloid differentiation protein-2 (MD-2), LPS binding protein (LBP) and CD14 (Jiang et al., 2005; Kobayashi et al., 2006; Park et al., 2009) . Docking the LPS-CD14 complex onto the TLR4/MD2 complex initiates signaling through both the myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF)
pathways (Kobayashi et al., 2006) . MyD88-dependent signaling activates nuclear factor-kappa B (NF-κB), which leads to the production of proinflammatory cytokines, including IL-6, tumor necrosis factor-α (TNFα) and IL-12. Alternatively, TLR4 signaling can utilize the TRIF pathway, which acts through interferon (IFN) regulatory factor (IRF)-3, to promote the production of type I IFN (IFN α /β), IFN-inducible gene products, and an immune regulatory response (Yamamoto et al., 2004; Kobayashi et al., 2006) .
In light of their capability to activate innate immune responses, TLR ligands have been JPET #214312 implicated as potential immune modulating agents. These ligands can be used as immune activators such as vaccine adjuvants, and can also be used as inflammatory suppressants when delivered as functional receptor antagonists. Natural or semisynthetic TLR4 ligands, including LPS and monophosphoryl lipid A (MPLA), exhibit adjuvant activity when used with vaccine antigens (Mata-Haro et al., 2007; McAleer and Vella, 2010 ) that confer protection against viruses. Eritoran, (also known as E5564)-a synthetic TLR4 antagonist, did not improve survival in sepsis patients in a phase III clinical trial (Barochia et al., 2011; Opal et al., 2013) , but reduced influenza-induced lethality in mice (Shirey et al., 2013) . Alternatively
repeatedly can prevent or attenuate autoimmune disease in various mouse models (Hayashi et al., 2009 ). However, the clinical development of TLR4 ligands as immunotherapeutic agents has been impeded by their inflammatory side effects, which have been difficult to control using LPS and its semi-synthetic derivatives.
A synthetic low molecular weight ligand for TLR4 would be more amenable to structural modification and formulation to attain the desired immunosuppressant, or immunostimulatory profile with limited toxicity, and oral bioavailability could be obtained. Hence, our laboratory conducted a cell-based high throughput screening (HTS) campaign using a library with over JPET #214312 BMDC and BMDM were prepared from C57BL/6 mice as described (Wu et al., 2007) . BMDC (10 5 cells per well) or BMDM were plated in 96-well plates in 200 μ L of complete RPMI1640.
The cells were incubated with graded concentrations of the compounds for 18 h at 37 °C, 5%
CO 2 . After 18 h incubation, the cell culture supernatants were collected. LPS (purified LPS, 10 ng/mL, Invivogen) or MPLA (1 μ g/mL synthetic MPLA, Invivogen), (S)-(2,3-bis (Guma et al., 2010) .
Pharmacokinetic studies
Mice were administered 1Z105 or 1Z88 intravenously (i.v.) (0.5 μ mol) or orally (p.o.) by gavage
(1 μ mol). Sera were collected at 5, 30, 60, 90, 120, and 240 min after administration, centrifuged (14,000 rpm for 10 min) and the resulting supernatant was mixed with an internal standard.
After dilution with twice the volume of methanol, the mixtures were centrifuged (14 000 rpm for 10 min) to remove precipitates and lyophilized. The dried samples were then reconstituted with a small volume of methanol and injected into an Agilent 1100 LC/MSD (Agilent, Santa Clara, CA) with a Supelco Discovery HS C18 column (5 µm, 50 x 2.1 mm id.) (Sigma-Aldrich, St.
Louis, MO). The samples were eluted with a linear gradient from 10:90 acetonitrile:water to 90:10 acetonitrile:water with 0.1 % triflouroacetic acid at a flow rate of 0.4 mL/min for 8 min and monitored by MS/MS. Compound concentrations in serum were calculated from peak area and extrapolated from prepared standards in serum with a lower limit of 10 nM. Area under curve (AUC) values were calculated using Prism 6.0 (GraphPad, San Diego CA) and used to determine oral bioavailability (Kerns and Di, 2008) .
Statistical Analysis
The data are represented as mean ± standard error of the mean (SEM 
Results
Cytokine induction by derivatives is TLR4/MD2 signaling dependent and CD14 independent
Through a cell based HTS campaign we previously identified compounds that shared a drug-like pyrimido [5,4-b] -indole scaffold (here designated 1Z65, 247543, and 247514), which targeted TLR4/MD2. We then synthesized 42 derivatives of a hit compound (1Z65) and performed a SAR using BMDC and a TLR4-NF-κB reporter cell line (Chan et al., 2013) . The derivatives that retained the ability to stimulate NF-κB in the reporter cell line were synthesized in sufficient quantity for target confirmation and functional analysis (Table 1 ). First we examined the components of the TLR4 receptor complex as the molecular target(s) of the synthesized analogs.
Given that the two TLR4 signaling pathways, through MyD88 and TRIF, result in IL-6 or type I IFN secretion respectively, we focused on the induction of IL-6 and IP-10, a surrogate marker of type I IFN production, by the compound. The ability to stimulate type I IFN was directly assayed vide infra and correlated with IP-10 ( Fig. 2 and supplemental Fig. 1 ). The cytokine production profiles of wild type (WT) stimulated BMDCs clustered into two distinct groups ( Fig. 1A and B) . 1Z105, 1Z103, 1Z82, 1Y82 and the resynthesized hit compound, 1Z65, induced high levels of IL-6, IP-10 and type 1 IFN (Group 1), whereas 1Z88, 1Z104 and two compounds from the original library (247543, and 247524) induced only low levels of IL-6 but retained the ability to induce moderate levels of IP-10 and type I IFN (Group 2).
Although TLR4 transmits an intracellular signal, there is a variable requirement by individual ligands for the MD2 and CD14 accessory molecules to fully engage an activation signal (Lu et al., 2008) . MD2 is required for activation of NF-κB by LPS or MPLA (Kim et al., 2007; Ohto et al., 2007; Casella and Mitchell, 2013) . CD14 is expressed on the surfaces of macrophages, dendritic cells, and neutrophils as a glycosylphosphatidylinositol (GPI)-anchored JPET #214312
1 5 membrane protein, that cannot transmit a signal itself without a co-receptor. CD14 is also present in serum as a soluble isoform, which can also play a role in LPS recognition by TLR4/MD2 by recruiting ligands into the complex (Ulevitch and Tobias, 1995).
Hence, we tested the requirements for TLR4, MD2 and CD14 in stimulating cytokine secretion by the SAR derivatives using BMDC from TLR4, MD2 or CD14 null mice, compared to wild type (WT) mice. The induction of IL-6 and IP-10 by all SAR derivatives was abrogated in TLR4 and MD2 null BMDCs ( Fig. 1C-F) . However, the SAR derivatives induced similar levels of IL-6 and IP-10 from the CD14 null BMDCs compared to WT BMDCs ( Fig. 1G and 1H), whereas LPS was not able to stimulate CD14 null cells. In control experiments, a TLR7 ligand, 1V136, was able to stimulate TLR4, MD2 and CD14 null BMDCs to produce both cytokines at levels similar to WT cells.
TLR4/MD2 utilizes both the MyD88 and the TRIF signaling pathways. To test if the compounds were selective for one of these pathways, we stimulated BMDCs that were deficient in the respective adaptor molecules. None of the compounds elicited IL-6 in MyD88 null cells (Fig. 1I) ; however Group 1 compounds were able to stimulate IP-10 production in these cells (Fig. 1J ). In the TRIF mutant cells there was little if any cytokine production by the compounds ( Fig. 1K and 1L ). These data suggest that Group 1 compounds require MyD88 for IL-6 production and TRIF for IP-10 production and Group 2 compounds are dependent on the presence of both adaptors to induce cytokine production.
Lead candidate selection: 1Z105 and 1Z88
Since there were two distinct immunologic profiles observed when cells were tested with a single dose of SAR compounds, we examined whether these profiles were dose dependent and JPET #214312
1 6 evaluated type 1 IFN production directly. BMDC were treated with graded doses of the compounds (Supplemental Fig. 1 and Fig. 2A ), and IL-6 levels and type I IFN levels were measured in the supernatants. The cytokine production profiles again clustered into two distinct groups ( Fig.2A) . 1Z105, 1Z103, 1Z82, 1Y82 and the resynthesized hit compound, 1Z65, induced high levels of both IL-6, and type 1 IFN (Group 1); whereas 1Z88, 1Z104 and two compounds from the original library (247543, and 247524) induced low levels of IL-6 but retained the ability to induce moderate levels of type I IFN (Group 2). The Group 1 derivatives stimulated robust levels of IL-6 with EC50s of 0.16 µM and 0.27 µM respectively for 1Y82 and 1Z105. Of the Group 1 derivatives 1Y82 and 1Z105 were the most potent in inducing type I IFN with EC50s of 1.4 µM and 1.9 µM, respectively. Group 2 compounds stimulated little if any IL-6, but retained the ability to stimulate type I IFN to reach a level of approximately 60% of the Group 1 compounds. The EC50s for stimulating type I interferon were 4.9 and 5.5 µM for 1Z88
and 1Z104, respectively. Control wells included LPS (10 ng/mL) or MPLA (1 µg/mL), which stimulated IL-6 (17.3 ± 2.4 ng/mL and 3.8 ± 0.2 ng/mL respectively). The type 1 IFN level induced by MPLA (1 µg/mL) was 53 ± 1.5 AU.
To further support the selection of lead candidate compounds, the cytotoxicities of these compounds were evaluated by MTT assay using HepG2 cells (Supplemental Fig. 1G and H).
The viability of cells incubated with the group 1 compounds: 1Z65, 1Z82, 1Z103, 1Z105 and 1Y82 at 10 μ M were 38%, 59%, 93%, 99%, and 93% respectively compared to the vehicle control ( Fig. 2B ). Among the compounds in Group 2, 1Z104 was slightly cytotoxic at 10 μ M (89% of control viability) while the other compounds (1Z88, 247543, and 247514) did not show cytotoxicity in HepG2 cells (98 to 100%) (Fig. 2B ). Hence 1Z65, 1Z103, 1Z82, 1Y82 and 1Z104 exhibited cytoxicity in this assay and were thus excluded from in vivo studies.
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In the hit-to-lead phase of drug discovery, it is important to consider structural properties including molecular weight, lipophilicity (as measured by logP), polar surface area (PSA), and number of hydrogen bonds (both donors and acceptors) (Kerns and Di, 2008) . Retrospective computational studies of successful lead compounds have suggested the following criteria for inclusion in the lead selection process: MW<500, logP < 4.2, PSA < 100, H-bond donors < 5, Hbond acceptors < 9 (Kerns and Di, 2008) . With these criteria in mind, we compared the structural properties of the active compounds in Groups 1 and 2 and observed that 1Z105 and 1Z88 were among the best candidates in their respective groups (Table 1) . While essentially all of the compounds met the requirements of PSA < 100 and MW < 460, 1Z105 had fewer H-bonds and was less toxic than other members in its group and 1Z88 had a lower logP than other members in its group.
Based on chemical properties, relative potency and lack of cytotoxicity, 1Z105 (Group 1) and 1Z88 (Group 2) were proposed as candidates for further study. The potential for toxicity of these compounds was retested on primary BMDC using MTT. The viability for BMDC treated with 10 µM 1Z65, 1Z105, and 1Z88 were 47%, 92% and 122% respectively (Supplemental Figure 2 ).
Exposure to 1Z88 and 1Z105 desensitizes cells to subsequent TLR activation
As the lead compounds targeted the TLR4/MD2-MyD88 pathway, we tested their ability to interfere with subsequent TLR stimulation. Prior exposure of innate immune cells like monocytes/macrophages to LPS causes them to become refractory or hyposensitive to subsequent LPS challenge, a phenomenon called "LPS (endotoxin) tolerance". Pretreatment with a low dose of LPS can allow sustained SHIP phosphorylation and increase the expression of JPET #214312
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the IRAK decoy-IRAKM. These two mechanisms then limit the ability of TLR ligands to transmit a signal through the MyD88-NF-κB pathway (Medvedev et al., 2006; Bao and Liu, 2013 ).
We thus assessed whether 1Z105 and 1Z88 could functionally inhibit TLR4 activation at low drug concentrations. BMDM initially exposed to varying concentrations of 1Z105 or 1Z88 were restimulated with LPS and the IL-6 release ( Fig 3A) or IP-10 (Supplemental Figure 3) into the culture supernatant was measured. Pretreatment with as low as 0.63 µM 1Z105 significantly reduced the IL-6 secretion by subsequent challenge with LPS (Fig. 3A) . A similar inhibition was observed when 1Z88 was used, although 1Z88 required higher doses to desensitize BMDM to rechallenge. However, simultaneous delivery of LPS and 1Z105 or 1Z88 did not diminish NF-κ B activation in a reporter cell line (Supplemental figure 4).
Considering that 1Z105 and 1Z88 were able to desensitize cells to a TLR4 rechallenge, we also tested for the "cross tolerance" phenomenon in which pretreatment with a TLR ligand can limit signal transmission through MyD88-NF-κB by other TLRs. We chose doses of 1Z105 and 1Z88
that were able to fully suppress IL-6 ( (TLR7) and ODN1826 (TLR9), indicating that these compounds not only reduce subsequent TLR4 stimulation, but also attenuate signaling by other MyD88 dependent TLRs ( Figure 3B ).
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1Z105 is orally bioavailable, non-toxic and retains TLR tolerizing activity
We further evaluated the pharmacokinetics (PK) of 1Z105 and 1Z88. The serum concentrations of 1Z105 and 1Z88 after intravenous administration peaked right after injection (5 min) and declined within 60 min ( Fig. 4A and 4B ). Compound 1Z105, but not 1Z88, was also detectable in the serum after oral administration. The peak concentration was observed at 60 min (Fig. 4A) .
The AUC after intravenous and oral administration was 374 ± 111 and 84 ± 7 (mean ± SEM).
The calculated oral bioavailability of 1Z105 was 11%. Following oral administration, the concentration of 1Z105 in sera increased in a dose-dependent manner and the maximal sera concentration was detected at a 5 μ mol dose (Fig. 4C) .
The clinical development of TLR active agents as therapeutics has been hindered by their inflammatory side effects, due to release of TNF and other cytokines. Systemic cytokine induction narrows the therapeutic window needed to achieve an effective treatment dose (Engelich et al., 2001) . To study whether 1Z105 and 1Z88 stimulated in vivo pro-inflammatory cytokine release at the doses needed to suppress LPS stimulation, 1Z105 and 1Z88 were given i.p., and 1Z105 was also tested by oral administration. In prior studies peak levels of cytokine release in the sera of mice occurred about 1 to 2 h after i.p. injection. Sera at 2 h after injection had very low or undetectable levels of TNFα, IL-6, or IP-10 ( Fig. 4D-F (Fig. 4G ).
Beneficial effects of 1Z105 and 1Z88 on galactosamine induced liver toxicity
The lack of a pro-inflammatory response to systemic 1Z105 or 1Z88 administration suggested that these compounds might be useful in attenuating inflammation. To test this possibility, the endotoxin-induced liver injury model was used ( Fig. 5A and 5B). In this model mice that are primed with galactosamine succumb to acute hepatic inflammation and failure after injection with LPS, a TLR4 ligand. To assess if the TLR4/MD2 ligands could prevent toxicity in this model, WT mice were i.p. treated with 1Z105, 1Z88 or MPLA and challenged with LPS plus galactosamine. More than 80% of mice treated with 1Z105, 1Z88, and MPLA survived, while only 22% of vehicle treated mice survived 24 h after LPS/galactosamine challenge (Fig. 5A ).
This finding was mirrored by the levels of TNF release in the sera (Fig. 5B ).
1Z105 and 1Z88 were shown to be safe by lack of nonspecific immune activation ( Fig.   4D-F) . In a model of chemically induced liver failure, galactosamine is co-administered with LPS, and TLR4 ligation is required for lethality. 1Z105 was tested as a surrogate for LPS in this model. When 1Z105 was delivered with galactosamine at doses which were protective, no mortality of mice after administration with galactosamine was detected (Fig. 5C ).
1Z105 and 1Z88 prevent autoantibody induced arthritis
In rheumatoid arthritis, the production of cytokines and chemokines has been partially attributed to innate immune mechanisms. TLR4 has been identified as a prominent candidate This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 6 A and B) . The 1Z105 treatment significantly decreased histological inflammation, bone erosion and cartilage damage (Fig. 6 C-I ).
This article has not been copyedited and formatted. The final version may differ from this version. attributable to inhibition of MyD88 signaling by negative regulators. Thus while 1Z88 and 1Z105 are specific for TLR4, they exert broad anti-inflammatory effects.
Several TLR4 ligands, like MPLA, aminoalkyl glucosaminide phosphates (AGPs), Glucopyranosyl Lipid Adjuvant (GLA) and E6020 were developed as semi-synthetic vaccine adjuvants (Ismaili et al., 2002; Ishizaka and Hawkins, 2007; Johnson, 2008; Arias et al., 2012) .
These contain modified Lipid A scaffolds that are not absorbed from the gastrointestinal tract unless the intestinal epithelial barrier is compromised. Our PK study showed that 1Z105 was orally bioavailable and non-toxic at doses that inhibited inflammation. Further formulation should improve the oral adsorption of this compound.
Both orally or parenterally administered 1Z105 reduced TNFα release in sera by high dose LPS (20 μ g/animal) alone or after LPS challenge in galactosamine preconditioned mice.
The doses of 1Z105 that suppressed proinflammatory cytokine storm by subsequent LPS challenge did not cause proinflammatory cytokine release in sera. In preliminary experiments we have not yet achieved a toxic oral dose of 1Z105 in mice. Although MPLA is known as a detoxified form of LPS (Casella and Mitchell, 2013) , it has a narrower therapeutic window than 1Z105. In contrast to MPLA, 1Z105 did not cause any mortality when injected into mice preconditioned with galactosamine (Fig. 5) . These results document that 1Z105 is a safe and orally available TLR4 ligand that can restrain inflammatory processes that depend on MyD88 signaling.
The TLR4 antagonist Eritoran has been investigated for its ability to limit the cytokine storm produced by LPS release in Gram-negative bacterial infections (Kim et al., 2007; Barochia et al., 2011) . In recent clinical trials this approach has not improved patient survival (Opal et al., 2013) . However Eritoran does not inhibit MyD88 activation by TLR4 independent pathways, as 1Z88 and 1Z105 do. Orally active, and well-tolerated synthetic TLR modulators, such as 1Z105, might be useful in many non-infectious inflammatory diseases. Their relatively short duration of pharmacokinetics would allow for treatment interruption in the setting of an acute infection.
In summary, we have described synthetic low molecular weight TLR4 ligands, 1Z105
and 1Z88, that target the TLR4/MD2 complex. Although these drugs can elicit proinflammatory cytokine release in vitro at high concentrations, when used in vivo they inhibit the production of these cytokines by diverse stimuli that stimulate the MyD88 pathway. One of these molecules, 1Z105, was modestly orally bioavailable and reduced joint inflammation in murine model of arthritis.
JPET #214312 Supplemental Figure 1 . Dose dependent cytokine production and toxicity. WT C57BL/6 BMDC were plated at 1 ×105 cells/well and were incubated with graded concentrations of each compound overnight. IL-6 (A and B) and IP-10 (C and D) levels were measured by ELISA. Type 1 IFN levels were measured by IRSE reporter assay (E and F). Control wells included LPS (10ng/mL) or MPLA (1 µg/mL). Induction of IL-6 and IP-10 by LPS was 17.3 ± 2.4 ng/mL and 387 ± 16 pg/mL , respectively. Induction of IL-6 and IP-10 by MPLA were 3.8 ± 0.2 ng/mL and 106 ± 39 pg/mL, respectively. The type 1 IFN level induced by MPLA (1 µg/mL) was 53 ± 1.5 AU. Hep G2 cells in 96-well plates were exposed to compounds for 24 hours and cell viabilities were measured by a tetrazolium (MTT) assay (G and H). The OD(570-650) was 1.14 ± 0.01 for the vehicle control treated wells. All data shown are mean ± SEM of triplicates and representative of two independent experiments. 
Figure legends
